Long-term Outcome of Perianal Fistulizing Crohn's Disease Treated With Infliximab Guillaume Bouguen, Laurent Siproudhis, Emmanuel Gizard, Timothée Wallenhorst, Vincent Billioud, Jean–François Bretagne, Marc– André Bigard, Laurent Peyrin–Biroulet Clinical Gastroenterology and Hepatology Volume 11, Issue 8, Pages 975-981.e4 (August 2013) DOI: 10.1016/j.cgh.2012.12.042 Copyright © 2013 AGA Institute Terms and Conditions
Figure 1 Flow chart of the 156 patients. Clinical Gastroenterology and Hepatology 2013 11, 975-981.e4DOI: (10.1016/j.cgh.2012.12.042) Copyright © 2013 AGA Institute Terms and Conditions
Figure 2 Cumulative probability of first fistula closure. Clinical Gastroenterology and Hepatology 2013 11, 975-981.e4DOI: (10.1016/j.cgh.2012.12.042) Copyright © 2013 AGA Institute Terms and Conditions
Figure 3 Kaplan–Meier analysis of first fistula closure after IFX therapy initiation according to predictors identified by multivariate analysis. (A) Ileocolonic disease (L3). (B) Seton drainage duration. (C) Long-term treatment with IFX more than 118 weeks. (D) Combination therapy for immunosuppressant-naive patients. Clinical Gastroenterology and Hepatology 2013 11, 975-981.e4DOI: (10.1016/j.cgh.2012.12.042) Copyright © 2013 AGA Institute Terms and Conditions
Figure 4 Cumulative probability of fistula recurrence among the 108 patients who experienced fistula closure. Clinical Gastroenterology and Hepatology 2013 11, 975-981.e4DOI: (10.1016/j.cgh.2012.12.042) Copyright © 2013 AGA Institute Terms and Conditions
Supplementary Figure 1 Kaplan–Meier analysis of sustained fistula closure after IFX initiation according to predictors identified by multivariate analysis. Clinical Gastroenterology and Hepatology 2013 11, 975-981.e4DOI: (10.1016/j.cgh.2012.12.042) Copyright © 2013 AGA Institute Terms and Conditions